ArticleHealth science reports2026
Beyond Weight Loss: Tirzepatide as a Metabolic Disease-Modifying Strategy for Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide and a major contributor to liver-related morbidity and mortality. Its progressive subtype, metabolic dysfunction-associated steatohepatitis (MASH), is characterized by hepatocellular injury, inflammation, and fibrosis, which may ultimately progress to cirrhosis and hepatocellular carcinoma. Despite the rapidly increasing global burden of MASH, effective pharmacological therapies remain limited. Lifestyle modification remains the cornerstone of management; however, achieving and maintaining the degree of sustained weight loss required for meaningful histological improvement is challenging in routine clinical practice. Objective: This perspective review evaluates the emerging therapeutic potential of tirzepatide in the management of MASH. Methods: Relevant mechanistic studies, clinical trials, and recent literature published between 2015 and 2025 were reviewed to evaluate the emerging role of tirzepatide and incretin-based therapies in metabolic liver disease. Results: Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that produces substantial metabolic benefits, including improved glycemic control, enhanced insulin sensitivity, and significant weight reduction. These effects directly address key drivers of MASLD and MASH, including hepatic lipid accumulation, insulin resistance, and systemic inflammation. Emerging clinical evidence, particularly from the SYNERGY-NASH trial, suggests that tirzepatide may promote resolution of steatohepatitis and improvement in fibrosis in patients with biopsy-confirmed MASH. Conclusion: Tirzepatide represents a promising metabolic disease-modifying therapy for MASH. Nevertheless, larger and longer-term clinical studies are needed to establish its durability of benefit, long-term safety, and optimal role within evolving treatment strategies for metabolic liver disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.